Home
Live Updates
Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma : comparemela.com
Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma
The COMBI-AD dataset is the longest follow-up to date of adjuvant treatment for patients with stage III melanoma.
Related Keywords
Australia ,
Georgina ,
Western Australia ,
Sydney ,
New South Wales ,
Innovent Biologics ,
Pierre Fabre ,
Boehringer Ingelheim ,
Bristol Myers Squibb ,
Novartis ,
University Of Sydney ,
Astrazeneca ,
Amgen ,
New England Journal ,
Array Biopharma ,
Evaxion Biotech ,
Highlight Therapeutics ,
Immunocore Ireland ,
Merch Sharp ,
comparemela.com © 2020. All Rights Reserved.